Drug Profile
SM 17466
Alternative Names: SM-17466Latest Information Update: 30 Aug 2007
Price :
$50
*
At a glance
- Originator Sumitomo Pharmaceuticals
- Class Antibacterials; Carbapenems
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 03 Aug 1998 No-Development-Reported for Bacterial infections in Japan (Unknown route)
- 07 Jun 1995 Preclinical development for Bacterial infections in Japan (Unknown route)